Bio-Rad Laboratories, Inc. Class A Common Stock vs Tencent Music Entertainment Group - ADR — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.05 (market cap $9.43B), while Tencent Music Entertainment Group - ADR trades at $8.38 (market cap $16.09B). The key difference: Tencent Music Entertainment Group - ADR is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays a 2.75% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | TME | |
|---|---|---|
Market Cap | $9.43B | $16.09B |
Sector | Health | Media |
52-Week High | $356.25 | $26.36 |
52-Week Low | $241.71 | $8.16 |
Enterprise Value | $9.18B | $14.05B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
TME stock trades at $9.90, up 3.88% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $8.9 billion (up 6% year-over-year) and net profit of $2.5 billion, beating EPS estimates. Financials show strong profitability with a net income margin of 26.28% and a P/E ratio of 10.29, indicating potential undervaluation. Recent news highlights mixed quarterly performance with revenue growth slowing but profit beating expectations.
The outlook for TME is cautiously optimistic, supported by solid fundamentals and bullish analyst sentiment, but risks include intensifying competition, user churn, and AI-related copyright issues. Upside potential exists from premium membership growth and ecosystem integration, though near-term volatility may persist due to market conditions and operational challenges.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →